Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)
Year: 2013
Type: article
Source: Blood
Authors: Jacob P. Laubach, Jesús F San Miguel, Pieter Sonneveld, Robert Z. Orlowski, Philippe Moreau, Laura Rosiñol, Javid J Moslehi, Edward A Faber, Peter M Voorhees, Loreta Marquez, Avinash Desai, Helgi van de Velde, Jennifer Elliott, Hongliang Shi, Edward Dow, Nishith Jobanputra, Dixie-Lee Esseltine, Liviu Niculescu, Kenneth C. Anderson, Sagar Lonial, Paul G. Richardson
Institutions: Dana-Farber Cancer Institute, Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Erasmus MC, The University of Texas MD Anderson Cancer Center, Centre Hospitalier Universitaire de Nantes, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Brigham and Women's Hospital, Oncology Hematology Care, University of North Carolina at Chapel Hill, Janssen Research & Development (United States), Janssen (Belgium), Takeda Oncology (United States), Winship Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2415425894